SCHEMBL22485142

SCHEMBL22485142

C/C=N/N1CCN(CC)CC1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.33
MAPK1 P28482 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
ALDH1A1 P00352 2/20 0.32
KMT2A Q03164 2/20 0.32
CYP2D6 P10635 1/20 0.32
GAA P10253 3/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
KDM4E B2RXH2 1/20 0.31
MAPT P10636 1/20 0.31
RAD52 P43351 1/20 0.31
GFER P55789 1/20 0.31
TDP1 Q9NUW8 1/20 0.30
NPC1 O15118 1/20 0.30
POLB P06746 1/20 0.30
ALOX15 P16050 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22482237 0.79 SMN1; SMN2 (0.32) CHRNA7MAPK1L3MBTL1ALDH1A1KMT2A
SCHEMBL21428541 0.76 MAPK1 (0.31) CHRNA7MAPK1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL13616545 0.74 MAOB (0.33)
SCHEMBL6657817 0.72 CHRNA7 (0.48) CHRNA7ALDH1A1KMT2ACYP2D6GAA
SCHEMBL577052 0.72 CHRNA7 (0.48) CHRNA7ALDH1A1KMT2ACYP2D6GAA
SCHEMBL577415 0.72 CHRNA7 (0.48) CHRNA7ALDH1A1KMT2ACYP2D6GAA
SCHEMBL262312 0.72
SCHEMBL84808 0.72 CHRNA7 (0.48) CHRNA7ALDH1A1KMT2ACYP2D6GAA
SCHEMBL9975308 0.72 RAB9A (0.42) MAPK1L3MBTL1ALDH1A1KMT2AGAA
SCHEMBL6853642 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11345713-B2 Compounds as modulators of TLR2 signaling NEUROPORE THERAPIES, INC. (US) 2022-05-31 US disclosed
US-20210024539-A1 COMPOUNDS AS MODULATORS OF TLR2 SIGNALING NEUROPORE THERAPIES, INC. (US) 2021-01-28 US disclosed
WO-2020198368-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING NEUROPORE THERAPIES, INC. (US) 2020-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11345713-B2 Compounds as modulators of TLR2 signaling TLR2, TLR4, TLR3 CHRNA7 2352/4885MAPK1 512/4885L3MBTL1 3126/4885
US-20210024539-A1 COMPOUNDS AS MODULATORS OF TLR2 SIGNALING TLR2, TLR4, TLR3 CHRNA7 2352/4885MAPK1 512/4885L3MBTL1 3126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.